Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal ...
Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.
TipRanks on MSN
Omeros Signs Major Deal with Novo Nordisk
Omeros ( ($OMER) ) has issued an update. On October 10, 2025, Omeros Corporation entered into an Asset Purchase and License Agreement with Novo ...
A research team has outlined how synthetic biology can accelerate discoveries in plant–microbe interactions, offering ...
GlobalData on MSN
Novo Nordisk snaps up Omeros’ rare disease asset for up to $2.1bn
The biotech is also eligible to receive up to $2.1bn in development and commercial milestone payments from Novo Nordisk, ...
Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a ...
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patientsReal-world evidence and long-term data reinforce VYVGART’s sustained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback